Sign In
Buy FBIO
$2.61
-0.0400 (-1.51%)
At Close: Jun 03, 2026
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
04:01pm, Wednesday, 14'th May 2025
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescription
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
04:15pm, Tuesday, 13'th May 2025
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
04:01pm, Wednesday, 07'th May 2025
Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
08:00am, Wednesday, 07'th May 2025
MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term v
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
04:01pm, Tuesday, 01'st Apr 2025
SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily
Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates
06:50pm, Monday, 31'st Mar 2025
Fortress Biotech (FBIO) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.53 per share a year ago.
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
04:05pm, Monday, 31'st Mar 2025
Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidia
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
08:30am, Friday, 28'th Mar 2025
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first
Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript
07:39pm, Wednesday, 26'th Mar 2025
Fortress Biotech, Inc. (NASDAQ:FBIO ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder,
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
04:01pm, Wednesday, 26'th Mar 2025
FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey M
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
04:01pm, Wednesday, 19'th Mar 2025
Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strate
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
08:30am, Wednesday, 12'th Mar 2025
SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling an
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
06:41pm, Monday, 10'th Mar 2025
NEW YORK , March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceut
